1. Pink Sheet
  2. >>Geography

Medicare Add-On Payments For Praxbind, Andexanet Under Consideration

 
• By Cathy Kelly

Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.

Boehringer Ingelheim GMBH andPortola Pharmaceuticals Inc. are seeking Medicare new technology add-on payments beginning in 2017 for their respective anticoagulant drug antidotes Praxbind (idarucizumab) and andexanet alfa.

The Centers for Medicare and Medicaid Services announced it is considering new technology add-payments (NTAPs) for the two treatments in its proposed rule setting Medicare inpatient hospital payment policies for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America